Clients

Prothena Corporation

Company Snapshot: Prothena Corporation

PRTA
Last Change Volume High Low

Company Overview

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

Client News

  1. Jun 25 2018 Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
  2. Jun 25 2018 Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
  3. Jun 19 2018 Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology
  4. May 24 2018 Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline